These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 9645569)
1. Big BU/CY is associated with a favorable long-term outcome in patients allotransplanted for chronic myelogenous leukemia in chronic phase. Bonini A; Bandini G; Rosti G; Rondelli D; Testoni N; Remiddi C; Motta MR; Rizzi S; Mangianti S; Campanini E; Zuffa E; Tura S Bone Marrow Transplant; 1998 Jun; 21(11):1085-9. PubMed ID: 9645569 [TBL] [Abstract][Full Text] [Related]
2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682 [TBL] [Abstract][Full Text] [Related]
3. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
4. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568 [TBL] [Abstract][Full Text] [Related]
5. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663 [TBL] [Abstract][Full Text] [Related]
6. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Doney KC; Chauncey T; Appelbaum FR; Bone Marrow Transplant; 2002 May; 29(10):817-23. PubMed ID: 12058231 [TBL] [Abstract][Full Text] [Related]
7. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bertz H; Potthoff K; Mertelsmann R; Finke J Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109 [TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning. Zaretsky Y; Rifkind J; Lockwood G; Tsang R; Kiss T; Hasegawa W; Fyles G; Tejpar I; Loach D; Minden M; Messner H; Lipton JH Bone Marrow Transplant; 2007 Sep; 40(5):423-30. PubMed ID: 17603516 [TBL] [Abstract][Full Text] [Related]
10. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990 [TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952 [TBL] [Abstract][Full Text] [Related]
12. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792 [TBL] [Abstract][Full Text] [Related]
13. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272 [TBL] [Abstract][Full Text] [Related]
14. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
16. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [TBL] [Abstract][Full Text] [Related]
17. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786 [TBL] [Abstract][Full Text] [Related]
18. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650 [TBL] [Abstract][Full Text] [Related]
19. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899 [TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]